Huntsville, AL (PRWEB) March 22, 2012
Diatherix Laboratories and Microarrays Inc. (MI) jointly announce they have entered a strategic partnership to develop industry leading infectious disease diagnostic assays.
The ever-increasing prevalence of infectious and drug-resistant organisms requires that diagnostic platforms be highly adaptable and progressively more comprehensive.
With this partnership the companies will integrate their proprietary technologies to develop and continually update diagnostic assays, which will achieve the maximum flexibility necessary to better serve the healthcare community.
“This collaboration brings together all of the necessary modalities of discovery, development and implementation for dynamic state of the art diagnostic assays,” said Joel Peek, Ph.D., MI’s chief executive officer. Diatherix’s chief executive officer, Dennis Grimaud, added that “the combination of Diatherix’s unique diagnostic identification technology combined with MI’s extremely sensitive detection platform will not only assist physicians in accurate testing results for infectious disease, but will also assist in lowering the overall cost of diagnostic testing”.
Diatherix Laboratories, Inc. is a CLIA certified high complexity reference laboratory providing infectious disease diagnostics. Diatherix’s innovative testing technology can diagnose a wide variety of infectious diseases faster and more accurately than traditional testing. Their unique analysis platform has been proven to result in better patient outcomes and significant hospital savings.
MI is an emerging leader in molecular diagnostics and analysis of DNA and proteins. MI’s innovations in array-based technologies have been applied in analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.